Tiny study probes why some MS patients react to their medication
NCT ID NCT06310343
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study involved 15 people with relapsing-remitting multiple sclerosis who were already taking alemtuzumab. Researchers measured anti-drug antibodies in their blood over 24 months to see if these antibodies affect treatment or cause infusion reactions. The goal was to better understand how the body responds to the drug, not to test a new therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
alemtuzumab
What this could lead to
If successful, this could help doctors understand why some MS patients have infusion reactions to alemtuzumab and how to manage treatment better.
What could go wrong
This is a very small, completed observational study with only 15 participants, so results may not apply to all MS patients. It does not test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING - REMITTING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barts Health NHS Trust
London, Second Floor Neurophys Dept, United Kingdom